Perrigo RECEIVES FDA Approval and 2 Stocks Breaking to 52-Week Highs

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Perrigo Company (NASDAQ:PRGO) shares closed up 1.28 percent at $116.76, on word that it has received final FDA approval for its abbreviated new drug application for clindamycin phosphate and benzoyl peroxide 1.2 percent / 5 percent topical gel, which represents the generic equivalent of Duac Gel. The shares have traded in the past 52 weeks between $75.89 and $116.50.

Don’t Miss: ARENA SHARES EXPLODE! First U.S. Diet Drug Approved in 13 Years.

Unifirst Corp. (NYSE:UNF) forecasts its fiscal year 2012 revenue in a range of $1.252 billion and 1.257 billion, against a consensus of $1.24 billion. Shares closed at $62.99, which represents a rise of 9.74 percent on the day, having been traded between $42.84 and $62.98 in the last 52 weeks.

Vivus (NASDAQ:VVUS) shares jumped 7.35 percent on the day and closed at $28.33, in sympathy with Arena’s FDA approval of Belviq, says Wells Fargo. The stocks have been traded between $6.13 and $27.95, in the past 52 weeks.

Don’t Miss: Apple Investors SMIRK at Samsung.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business